<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The transformation of follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (FL) to high-grade histology occurs in up to 70% of FL patients </plain></SENT>
<SENT sid="1" pm="."><plain>Studies reporting outcomes of transformed FL patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT) are scant </plain></SENT>
<SENT sid="2" pm="."><plain>Eight FL patients with histologically confirmed transformation to diffuse large B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> underwent HSCT at our institution </plain></SENT>
<SENT sid="3" pm="."><plain>The median age was 56 years (range 44-63 years) </plain></SENT>
<SENT sid="4" pm="."><plain>Median follow-up is 60 months </plain></SENT>
<SENT sid="5" pm="."><plain>Progression free survival and overall survival at 4-years for patients undergoing allogeneic HSCT is 56% and 66%, respectively </plain></SENT>
<SENT sid="6" pm="."><plain>Four patients developed grade II-IV <z:hpo ids='HP_0011009'>acute</z:hpo> GVHD, whereas four patients had extensive <z:hpo ids='HP_0011010'>chronic</z:hpo> GVHD </plain></SENT>
<SENT sid="7" pm="."><plain>Day 100 and overall non-relapse mortality rate was 12.5% and 25%, respectively </plain></SENT>
<SENT sid="8" pm="."><plain>Allogeneic HSCT appears feasible in patients with transformed FL and is associated with acceptable treatment-related mortality and low relapse rates </plain></SENT>
</text></document>